Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

720 ARTÍCULOS , VIENDO DEL 151 AL 165

Developing theragnostics for Alzheimer's disease: Insights from cancer treatment

Lee HJ, Choi HJ, Jeong YJ, Na YH, Hong JT, Han JM, Hoe HS, Lim KH.

Int J Biol Macromol. 2024 Jun;269(Pt 2):131925. doi: 10.1016/j.ijbiomac.2024.131925. Epub 2024 Apr 27.

Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease

Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Panza F.

Expert Opin Drug Discov. 2024 Jun;19(6):639-647. doi: 10.1080/17460441.2024.2348142. Epub 2024 Apr 29.

Membrane interactions in Alzheimer's disease treatment strategies with multitarget molecules

Zambrano P.

Bioorg Chem. 2024 Jun;147:107407. doi: 10.1016/j.bioorg.2024.107407. Epub 2024 Apr 26.

The broken Alzheimer's disease genome

Gouveia Roque C, Phatnani H, Hengst U.

Cell Genom. 2024 May 8;4(5):100555. doi: 10.1016/j.xgen.2024.100555. Epub 2024 May 1.

Role of vitamin B12 and folic acid in treatment of Alzheimer's disease: a meta-analysis of randomized control trials

Lee CY, Chan L, Hu CJ, Hong CT, Chen JH.

Aging (Albany NY). 2024 May 2;16(9):7856-7869. doi: 10.18632/aging.205788. Epub 2024 May 2.

Development of nanomedicines for the treatment of Alzheimer's disease: Raison d'être, strategies, challenges and regulatory aspects

Mazahir F, Alam MI, Yadav AK.

Ageing Res Rev. 2024 Jul;98:102318. doi: 10.1016/j.arr.2024.102318. Epub 2024 May 4.

"Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies

Dickson SP, Haaland B, Mallinckrodt CH, Dubois B, O'Keefe P, Morgan M, Peters O, Fernández Santana Iii A, Harrison J, Schneeberger A, Hendrix S.

J Prev Alzheimers Dis. 2024;11(3):529-536. doi: 10.14283/jpad.2024.64.

Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey

Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A, Iwatsubo T.

J Prev Alzheimers Dis. 2024;11(3):661-671. doi: 10.14283/jpad.2024.48.

Interpretation of 10 years of Alzheimer's disease genetic findings in the perspective of statistical heterogeneity

Gao S, Wang T, Han Z, Hu Y, Zhu P, Xue Y, Huang C, Chen Y, Liu G.

Brief Bioinform. 2024 Mar 27;25(3):bbae140. doi: 10.1093/bib/bbae140.

Promoting Alzheimer's disease research and therapy with stem cell technology

Cao Z, Kong F, Ding J, Chen C, He F, Deng W.

Stem Cell Res Ther. 2024 May 7;15(1):136. doi: 10.1186/s13287-024-03737-w.

Passive immunotherapy for Alzheimer's disease: challenges & future directions

Yi LX, Tan EK, Zhou ZD.

J Transl Med. 2024 May 7;22(1):430. doi: 10.1186/s12967-024-05248-x.

CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment

Tripathi S, Sharma Y, Rane R, Kumar D.

CNS Neurol Disord Drug Targets. 2024;23(12):1405-1424. doi: 10.2174/0118715273283786240408034408.

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Rishabh, Rohilla M, Bansal S, Bansal N, Chauhan S, Sharma S, Goyal N, Gupta S.

Eur J Neurosci. 2024 Jul;60(1):3466-3490. doi: 10.1111/ejn.16360. Epub 2024 May 10.

PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease

Kumar M, Sharma AA, Datusalia AK, Khatik GL.

Med Chem. 2024;20(8):781-798. doi: 10.2174/0115734064295063240422100615.

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease

Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, Purcell D, Dhadda S, Irizarry M, Kramer L.

Alzheimers Res Ther. 2024 May 10;16(1):105. doi: 10.1186/s13195-024-01441-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias